Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($5.20) EPS for the quarter, missing analysts’ consensus estimates of ($3.40) by ($1.80), FiscalAI reports. The firm had revenue of $9.44 million during the quarter, compared to analyst estimates of $9.60 million. Sunshine Biopharma had a negative net margin of 17.94% and a negative return on equity of 26.36%.
Sunshine Biopharma Trading Up 3.3%
NASDAQ SBFM traded up $0.09 during trading hours on Thursday, hitting $2.84. The company’s stock had a trading volume of 51,640 shares, compared to its average volume of 120,977. The company has a market capitalization of $624,800.00, a PE ratio of -0.01 and a beta of 1.32. Sunshine Biopharma has a 52 week low of $2.53 and a 52 week high of $464.00. The company’s 50-day simple moving average is $10.44 and its two-hundred day simple moving average is $98.38.
Analyst Ratings Changes
A number of brokerages have recently weighed in on SBFM. Wall Street Zen raised Sunshine Biopharma to a “hold” rating in a research report on Saturday, October 31st. Weiss Ratings raised shares of Sunshine Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, October 28th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce”.
View Our Latest Report on SBFM
Sunshine Biopharma Company Profile
Sunshine Biopharma, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors. In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations.
Read More
- Five stocks we like better than Sunshine Biopharma
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
